Mass spectrometry-based proteomic profiling of lung cancer

Proceedings of the American Thoracic Society

Volumn 6, Issue 2, 2009, Pages 159-170

  Ocak, Sebahat ^a   Chaurand, Pierre ^b   Massion, Pierre P ^a,c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Proteome; Translational research

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; PROTEOME;

ASPIRATION BIOPSY; CANCER CELL; CANCER DIAGNOSIS; CONFERENCE PAPER; DATA ANALYSIS; DISEASE MARKER; ELECTROSPRAY; GEL ELECTROPHORESIS; HIGH THROUGHPUT SCREENING; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEOMICS; SENSITIVITY ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; HUMANS; LUNG NEOPLASMS; MASS SPECTROMETRY; PROTEOMICS;

EID: 65349124101     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200809-108LC     Document Type: Conference Paper

References (132)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355: 479-485.
3. Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, Palma J, Brody JS. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci USA 2004;101:10143-10148.
4. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003;123:115S-128S.
5. Giaccone G. Clinical impact of novel treatment strategies. Oncogene 2002;21:6970-6981.
6. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
7. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2005;23:3270-3278.
8. Chanin TD, Merrick DT, Franklin WA, Hirsch FR. Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. Curr Opin Pulm Med 2004;10:242-247.
9. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002;8:2298-2305.
10. Beavis RC, Chait BT. Rapid, sensitive analysis of protein mixtures by mass spectrometry. Proc Natl Acad Sci USA 1990;87:6873-6877.
11. McCormack AL, Schieltz DM, Goode B, Yang S, Barnes G, Drubin D, Yates JR III. Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal Chem 1997;69:767-776.
12. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, Yates JR III. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999;17:676-682.
13. Wolters DA, Washburn MP, Yates JR III. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001;73:5683-5690.
14. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19:242-247.
15. Liebler DC. Shotgun mass spec goes independent. Nat Methods 2004;1: 16-17.
16. March RE. An introduction to quadrupole ion trap mass spectrometry. J Mass Spectrom 1997;32:351-369.
17. Schwartz JC, Senko MW, Syka JE. A two-dimensional quadrupole ion trap mass spectrometer. J Am Soc Mass Spectrom 2002;13:659-669.
18. Amster IJ. Fourier transform mass spectrometry. J Mass Spectrom 1996;31:1325-1337.
19. Cooper HJ, Hakansson K, Marshall AG. The role of electron capture dissociation in biomolecular analysis. Mass Spectrom Rev 2005;24: 201-222.
20. Mayya V, Rezaul K, Cong YS, Han D. Systematic comparison of a two- dimensional ion trap and a three-dimensional ion trap mass spectrometer in proteomics. Mol Cell Proteomics 2005;4:214-223.
21. Comisaro MB, Marshall AG. Fourier-transform ion-cyclotron resonance spectroscopy. Chem Phys Lett 1974;25:282-283.
22. Marshall AG. Milestones in fourier transform ion cyclotron resonance mass spectrometry technique development. Int J Mass Spectrom 2000; 200:331-356.
23. Syka JEP, Marto JA, Bai DL, Horning S, Senko MW, Schwartz JC, Ueberheide B, Garcia B, Busby S, Muratore T, et al. Novel linear quadrupole ion trap/FT mass spectrometer: performance characterization and use in the comparative analysis of histone H3 post- translational modifications. J Proteome Res 2004;3:621-626.
24. Hu QZ, Noll RJ, Li HY, Makarov A, Hardman M, Cooks RG. The orbitrap: a new mass spectrometer. J Mass Spectrom 2005;40:430-443.
25. Macek B, Waanders LF, Olsen JV, Mann M. Top-down protein sequencing and ms3 on a hybrid linear quadrupole ion trap-orbitrap mass spectrometer. Mol Cell Proteomics 2006;5:949-958.
26. Olsen JV, de Godoy LMF, Li GQ, Macek B, Mortensen P, Pesch R, Makarov A, Lange O, Horning S, Mann M. Parts per million mass accuracy on an orbitrap mass spectrometer via lock mass injection into a c-trap. Mol Cell Proteomics 2005;4:2010-2021.
27. Yates JR, Cociorva D, Liao LJ, Zabrouskov V. Performance of a linear ion trap-orbitrap hybrid for peptide analysis. Anal Chem 2006;78:493- 500.
28. Chaurand P, Schwartz SA, Caprioli RM. Profiling and imaging proteins in tissue sections by MS. Anal Chem 2004;76:87A-93A.
29. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001;7:493-496.
30. Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM. New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res 2006;5:2889-2900.
31. Caprioli RM. Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res 2005; 65:10642-10645.
32. Chaurand P, Schwartz SA, Billheimer D, Xu BJ, Crecelius A, Caprioli RM. Integrating histology and imaging mass spectrometry. Anal Chem 2004;76:1145-1155.
33. Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 2004;165:1057-1068.
34. Chaurand P, Schwartz SA, Reyzer ML, Caprioli RM. Imaging mass spectrometry: principles and potentials. Toxicol Pathol 2005;33:92- 101.
35. Reyzer ML, Hsieh Y, Ng K, Korfmacher WA, Caprioli RM. Direct analysis of drug candidates in tissue by matrix-assisted laser de- sorption/ionization mass spectrometry. J Mass Spectrom 2003;38: 1081-1092.
36. Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL, Caprioli RM. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 2004;64:9093-9100.
37. Goodlett DR, Keller A, Watts JD, Newitt R, Yi EC, Purvine S, Eng JK, von Haller P, Aebersold R, Kolker E. Differential stable isotope labeling of peptides for quantitation and de novo sequence derivation. Rapid Commun Mass Spectrom 2001;15:1214-1221.
38. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope- coded affinity tags. Nat Biotechnol 1999;17:994-999.
39. Ji JY, Chakraborty A, Geng M, Zhang X, Amini A, Bina M, Regnier F. Strategy for qualitative and quantitative analysis in proteomics based on signature peptides. J Chromatogr B Analyt Technol Biomed Life Sci 2000;745:197-210.
40. Kirkpatrick DS, Gerber SA, Gygi SP. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005;35:265-273.
41. Mason DE, Liebler DC. Quantitative analysis of modified proteins by LC-MS-MS of peptides labeled with phenyl isocyanate. J Proteome Res 2003;2:265-272.
42. Munchbach M, Quadroni M, Miotto G, James P. Quantitation and facilitated de novo sequencing of proteins by isotopic N-terminal labeling of peptides with a fragmentation directing moiety. Anal Chem 2000;72:4047-4057.
43. Ong SE, Foster LJ, Mann M. Mass spectrometric-based approaches in quantitative proteomics. Methods 2003;29:124-130.
44. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, et al. Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive iso- baric tagging reagents. Mol Cell Proteomics 2004;3:1154-1169.
45. Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, Hirohashi S, Yamada T. Label-free quantitative proteomics using large peptide data sets generated by nano-flow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006;5:1338- 1347.
46. Ru QHC, Zhu LWA, Silberman J, Shriver CD. Label-free semi- quantitative peptide feature profiling of human breast cancer and breast disease sera via two-dimensional liquid chromatography-mass spectrometry. Mol Cell Proteomics 2006;5:1095-1104.
47. Silva JC, Gorenstein MV, Li GZ, Vissers JPC, Geromanos SJ. Absolute quantification of proteins by LCMSE - a virtue of parallel MS acquisition. Mol Cell Proteomics 2006;5:144-156.
48. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, Resing KA, Ahn NG. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005;4:1487-1502.
49. Gade D, Thiermann J, Markowsky D, Rabus R. Evaluation of twodimensional difference gel electrophoresis for protein profiling. J Mol Microbiol Biotechnol 2003;5:240-251.
50. Lilley KS, Friedman DB. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 2004;1:401-409.
51. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M. Validation and development of fluorescence two-dimensional differential gel electro- phoresis proteomics technology. Proteomics 2001;1:377-396.
52. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997;18:2071-2077.
53. Von Eggeling F, Gawriljuk A, Fiedler W, Ernst G, Claussen U, Klose J, Romer I. Fluorescent dual colour 2D-protein gel electrophoresis for rapid detection of differences in protein pattern with standard image analysis software. Int J Mol Med 2001;8:373-377.
54. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44.
55. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM. Proteome analysis of human colon cancer by two- dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004;4:793-811.
56. Friedman DB, Stauff DL, Pishchany G, Whitwell CW, Torres VJ, Skaar EP. Staphylococcus aureus redirects central metabolism to increase iron availability. PLoS Pathog 2006;2:e87.
57. Friedman DB, Wang SE, Whitwell CW, Caprioli RM, Arteaga CL. Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and erbb2 signaling. Mol Cell Proteomics 2007;6:150-169.
58. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-588.
59. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and C-13- labeled peptide standards. Proteomics 2004;4:1175-1186.
60. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 2003;100:6940-6945.
61. Oh JM, Brichory F, Puravs E, Kuick R, Wood C, Rouillard JM, Tra J, Kardia S, Beer D, Hanash S. A database of protein expression in lung cancer. Proteomics 2001;1:1303-1319.
62. Bergman AC, Benjamin T, Alaiya A, Waltham M, Sakaguchi K, Franzen B, Linder S, Bergman T, Auer G, Appella E, et al. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 2000;21:679-686.
63. Gharib TG, Chen G, Wang H, Huang CC, Prescott MS, Shedden K, Misek DE, Thomas DG, Giordano TJ, Taylor JM, et al. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 2002;4:440-448.
64. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, Shedden KA, Misek DE, Taylor JM, Giordano TJ, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003;100:13537-13542.
65. Alfonso P, Catala M, Rico-Morales ML, Durante-Rodriguez G, MoroRodriguez E, Fernandez-Garcia H, Escribano JM, Alvarez-Fernandez E, Garcia-Poblete E. Proteomic analysis of lung biopsies: differential protein expression profile between peritumoral and tumoral tissue. Proteomics 2004;4:442-447.
66. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 2003;63:1652-1656.
67. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF Jr. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization- time of flight spectra analysis. Proteomics 2003;3:1720-1724.
68. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362:433-439.
69. Shyr Y, Kim K. Weighted flexible compound covariate method for classifying microarray data. In: Berrar D, editor. A practical approach to microarray data analysis. New York: Kluwer Academic; 2003. pp. 186-200.
70. Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, Mason SE, Olson SJ, Shyr Y, Carbone DP, et al. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. Proteomics Clin Appl 2008;2:1508-1517.
71. Rahman SM, Shyr Y, Yildiz PB, Gonzalez AL, Li H, Zhang X, Chaurand P, Yanagisawa K, Slovis BS, Miller RF, et al. Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med 2005;172:1556-1562.
72. Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 2007;99:858-867.
73. Amann JM, Chaurand P, Gonzalez A, Mobley JA, Massion PP, Carbone DP, Caprioli RM. Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser de- sorption ionization time-of-flight mass spectrometry. Clin Cancer Res 2006;12:5142-5150.
74. Groseclose MR, Massion PP, Chaurand P, Caprioli RM. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue micro- arrays using maldi imaging mass spectrometry. Proteomics 2008;8:3715- 3724.
75. Seemann MD, Beinert T, Furst H, Fink U. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer 1999;26:149-155.
76. Pastor A, Menendez R, Cremades MJ, Pastor V, Llopis R, Aznar J. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir J 1997;10:603-609.
77. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron- specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-1937.
78. Sidransky D, Irizarry R, Califano JA, Li X, Ren H, Benoit N, Mao L. Serum protein maldi profiling to distinguish upper aerodigestive tract cancer patients from control subjects. J Natl Cancer Inst 2003;95: 1711-1717.
79. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-446.
80. Mobley JA, Lam YW, Lau KM, Pais VM, L'Esperance JO, Steadman B, Fuster LM, Blute RD, Taplin ME, Ho SM. Monitoring the
81. serological proteome: the latest modality in prostate cancer detection. J Urol 2004;172:331-337.
82. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577.
83. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, et al. Serum proteomic patterns for detection of prostate cancer. JNatl Cancer Inst 2002;94:1576-1578.
84. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, Carbone DP. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993;85:2012-2018.
85. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
86. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-1304.
87. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE II. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;25:5578-5583.
88. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, et al. Diagnostic accuracy of maldi mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007;2:893-901.
89. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, Lau WH, Au JS, Law SC, Cheng WW, et al Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52.
90. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, et al Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84:845-856.
91. Khan N, Cromer CJ, Campa M, Patz EF Jr. Clinical utility of serum amyloid a and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 2004;101:379-384.
92. Benson MD, Eyanson S, Fineberg NS. Serum amyloid a in carcinoma of the lung. Cancer 1986;57:1783-1787.
93. Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 2008;31:133-139.
94. Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC. Application of serum seldi proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005;5:83.
95. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, et al. Mass spectrom- etry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.
96. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004;76:1560-1570.
97. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-1722.
98. Griese M, Noss J, Bredow Cv C. Protein pattern of exhaled breath condensate and saliva. Proteomics 2002;2:690-696.
99. Carpagnano GE, Foschino-Barbaro MP, Resta O, Gramiccioni E, Carpagnano F. Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology 2004;66:180- 184.
100. Carpagnano GE, Resta O, Foschino-Barbaro MP, Gramiccioni E, Carpagnano F. Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers 2002;17:141- 145.
101. Yamagata N, Shyr Y, Yanagisawa K, Edgerton M, Dang TP, Gonzalez A, Nadaf S, Larsen P, Roberts JR, Nesbitt JC, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003;9:4695-4704.
102. Tukey JW. Tightening the clinical trial. Control Clin Trials 1993;14: 266-285.
103. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, et al. Gene- expression profiles in hereditary breast cancer. N Engl J Med 2001; 344:539-548.
104. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847. (see comments).
105. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003;63:7113-7121.
106. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-1061. 106. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272- 1275.
107. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, Kobayashi R. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005;4:972-981.
108. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, Jacks K, Smith C, Kireeva I, Zhang R, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361-372.
109. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845- 867.
110. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Investigating diversity in human plasma proteins. Proc Natl Acad Sci USA 2005;102:10852-10857.
111. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, Su Q, McGrath AM, Estock MA, Parmar PP, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003;3:1345-1364.
112. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S. Multi- component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003;3:422-432.
113. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002;1:947-955.
114. Liu T, Qian WJ, Chen WN, Jacobs JM, Moore RJ, Anderson DJ, Gritsenko MA, Monroe ME, Thrall BD, Camp DG II, et al. Improved proteome coverage by using high efficiency cysteinyl peptide enrichment: the human mammary epithelial cell proteome. Proteomics 2005;5:1263-1273.
115. Shen Y, Jacobs JM, Camp DG II, Fang R, Moore RJ, Smith RD, Xiao W, Davis RW, Tompkins RG. Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal Chem 2004;76:1134-1144.
116. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096-1103.
117. Chen EI, Hewel J, Felding-Habermann B, Yates JR III. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MUDPIT). Mol Cell Proteomics 2006;5:53-56.
118. Jessani N, Niessen S, Wei BQ, Nicolau M, Humphrey M, Ji Y, Han W, Noh DY, Yates JR III, Jeffrey SS, et al. A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods 2005;2:691-697.
119. Fujii K, Nakano T, Kanazawa M, Akimoto S, Hirano T, Kato H, Nishimura T. Clinical-scale high-throughput human plasma proteome analysis: lung adenocarcinoma. Proteomics 2005;5:1150-1159.
120. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-5890.
121. Zhou Y, Aebersold R, Zhang H. Isolation of N-linked glycopeptides from plasma. Anal Chem 2007;79:5826-5837.
122. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-666.
123. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
124. Saghatelian A, Jessani N, Joseph A, Humphrey M, Cravatt BF. Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci USA 2004;101:10000-10005.
125. Jessani N, Humphrey M, McDonald WH, Niessen S, Masuda K, Gangadharan B, Yates JR III, Mueller BM, Cravatt BF. Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 2004;101:13756-13761.
126. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006;312:212-217.
127. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci USA 2007;104:5860- 5865.
128. Barr JR, Maggio VL, Patterson DG Jr, Cooper GR, Henderson LO, Turner WE, Smith SJ, Hannon WH, Needham LL, Sampson EJ. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem 1996;42: 1676-1682.
129. Wu CC, MacCoss MJ. Shotgun proteomics: tools for the analysis of complex biological systems. Curr Opin Mol Ther 2002;4:242-250.
130. Barnidge DR, Goodmanson MK, Klee GG, Muddiman DC. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res 2004;3:644-652.
131. Chaurand P, Friedman DB, Caprioli RM. Mass spectrometry in cancer biology. In: Mendelsohn J, Howley P, Israel M, Gray J, Thompson C, editors. The molecular basis of cancer, 3rd ed. New York: Elsevier; 2001. pp. 293-308.
132. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007;2:893-901.